FNAM Stock Overview
Engages in the research and identification of positively selected genes in humans, animals, and commercial crops. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Evolutionary Genomics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.0008 |
52 Week High | US$0.0008 |
52 Week Low | US$0.0008 |
Beta | 0 |
11 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | -99.91% |
5 Year Change | -99.95% |
Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Shareholder Returns
FNAM | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | 2.4% | 0.5% |
1Y | n/a | 15.6% | 30.7% |
Return vs Industry: Insufficient data to determine how FNAM performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how FNAM performed against the US Market.
Price Volatility
FNAM volatility | |
---|---|
FNAM Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 9.9% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 16.3% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: FNAM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine FNAM's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 3 | Steve Warnecke | www.evolgen.com |
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. It serves governmental organizations, non-profit foundations, and commercial entities.
Evolutionary Genomics, Inc. Fundamentals Summary
FNAM fundamental statistics | |
---|---|
Market cap | US$5.32k |
Earnings (TTM) | -US$2.25m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs FNAM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FNAM income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$2.25m |
Earnings | -US$2.25m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did FNAM perform over the long term?
See historical performance and comparison